Cargando…

Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program

Real-world data on lipid levels and treatment among adults with diabetes mellitus (DM) are relatively limited. We studied lipid levels and treatment status in patients with DM across cardiovascular disease (CVD) risk groups and sociodemographic factors. In the All of Us Research Program, we categori...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbarpour, Meleeka, Devineni, Divya, Gong, Yufan, Wong, Nathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966763/
https://www.ncbi.nlm.nih.gov/pubmed/36836203
http://dx.doi.org/10.3390/jcm12041668
_version_ 1784897097752903680
author Akbarpour, Meleeka
Devineni, Divya
Gong, Yufan
Wong, Nathan D.
author_facet Akbarpour, Meleeka
Devineni, Divya
Gong, Yufan
Wong, Nathan D.
author_sort Akbarpour, Meleeka
collection PubMed
description Real-world data on lipid levels and treatment among adults with diabetes mellitus (DM) are relatively limited. We studied lipid levels and treatment status in patients with DM across cardiovascular disease (CVD) risk groups and sociodemographic factors. In the All of Us Research Program, we categorized DM as (1) moderate risk (≤1 CVD risk factor), (2) high risk (≥2 CVD risk factors), and (3) DM with atherosclerotic CVD (ASCVD). We examined the use of statin and non-statin therapy as well as LDL-C and triglyceride levels. We studied 81,332 participants with DM, which included 22.3% non-Hispanic Black and 17.2% Hispanic. A total of 31.1% had ≤1 DM risk factor, 30.3% had ≥2 DM risk factors, and 38.6% of participants had DM with ASCVD. Only 18.2% of those with DM and ASCVD were on high-intensity statins. Overall, 5.1% were using ezetimibe and 0.6% PCSK9 inhibitors. Among those with DM and ASCVD, only 21.1% had LDL-C < 70 mg/dL. Overall, 1.9% of participants with triglycerides ≥ 150 mg/dL were on icosapent ethyl. Those with DM and ASCVD were more likely to be on high-intensity statins, ezetimibe, and icosapent ethyl. Guideline-recommended use of high-intensity statins and non-statin therapy among our higher risk DM patients is lacking, with LDL-C inadequately controlled.
format Online
Article
Text
id pubmed-9966763
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99667632023-02-26 Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program Akbarpour, Meleeka Devineni, Divya Gong, Yufan Wong, Nathan D. J Clin Med Article Real-world data on lipid levels and treatment among adults with diabetes mellitus (DM) are relatively limited. We studied lipid levels and treatment status in patients with DM across cardiovascular disease (CVD) risk groups and sociodemographic factors. In the All of Us Research Program, we categorized DM as (1) moderate risk (≤1 CVD risk factor), (2) high risk (≥2 CVD risk factors), and (3) DM with atherosclerotic CVD (ASCVD). We examined the use of statin and non-statin therapy as well as LDL-C and triglyceride levels. We studied 81,332 participants with DM, which included 22.3% non-Hispanic Black and 17.2% Hispanic. A total of 31.1% had ≤1 DM risk factor, 30.3% had ≥2 DM risk factors, and 38.6% of participants had DM with ASCVD. Only 18.2% of those with DM and ASCVD were on high-intensity statins. Overall, 5.1% were using ezetimibe and 0.6% PCSK9 inhibitors. Among those with DM and ASCVD, only 21.1% had LDL-C < 70 mg/dL. Overall, 1.9% of participants with triglycerides ≥ 150 mg/dL were on icosapent ethyl. Those with DM and ASCVD were more likely to be on high-intensity statins, ezetimibe, and icosapent ethyl. Guideline-recommended use of high-intensity statins and non-statin therapy among our higher risk DM patients is lacking, with LDL-C inadequately controlled. MDPI 2023-02-20 /pmc/articles/PMC9966763/ /pubmed/36836203 http://dx.doi.org/10.3390/jcm12041668 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Akbarpour, Meleeka
Devineni, Divya
Gong, Yufan
Wong, Nathan D.
Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title_full Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title_fullStr Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title_full_unstemmed Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title_short Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program
title_sort dyslipidemia treatment and lipid control in us adults with diabetes by sociodemographic and cardiovascular risk groups in the nih precision medicine initiative all of us research program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966763/
https://www.ncbi.nlm.nih.gov/pubmed/36836203
http://dx.doi.org/10.3390/jcm12041668
work_keys_str_mv AT akbarpourmeleeka dyslipidemiatreatmentandlipidcontrolinusadultswithdiabetesbysociodemographicandcardiovascularriskgroupsinthenihprecisionmedicineinitiativeallofusresearchprogram
AT devinenidivya dyslipidemiatreatmentandlipidcontrolinusadultswithdiabetesbysociodemographicandcardiovascularriskgroupsinthenihprecisionmedicineinitiativeallofusresearchprogram
AT gongyufan dyslipidemiatreatmentandlipidcontrolinusadultswithdiabetesbysociodemographicandcardiovascularriskgroupsinthenihprecisionmedicineinitiativeallofusresearchprogram
AT wongnathand dyslipidemiatreatmentandlipidcontrolinusadultswithdiabetesbysociodemographicandcardiovascularriskgroupsinthenihprecisionmedicineinitiativeallofusresearchprogram